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During pregnancy, the maternal organism is under the influence of tremendous endocrine
as well as immunological changes as an adaptation to the implanted and developing fetus.
In most cases, the maternal adaptations to pregnancy ensure both, the protection against
harmful pathogens and the tolerance toward the growing semi-allogeneic fetus. However,
under certain circumstances the unique hormonal milieu during pregnancy is causative of
a shift into an unfavorable direction. Of particular importance are cellular disorders previ-
ous to pregnancy that involve cell types known for their susceptibility to hormones. One
interesting cell type is the mast cell (MC), one of the key figures in allergic disorders. While
physiological numbers of MCs were shown to positively influence pregnancy outcome,
at least in mouse models, uncontrolled augmentations in quantity, and/or activation can
lead to pregnancy complications. Women that have the desire of getting pregnant and
been diagnosed with MC mediated disorders such as urticaria and mastocytosis or chronic
inflammatory diseases in which MCs are involved, including atopic dermatitis, asthma, or
psoriasis, may benefit from specialized medical assistance to ensure a positive pregnancy
outcome. In the present review, we address the course of pregnancy in women affected
by MC mediated or associated disorders.
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INTRODUCTION
Pregnancy represents a unique challenge for the maternal organ-
ism. Tremendous endocrine and immunological modifications
that occur as an adaptation to the implanted embryo ensure a
successful pregnancy outcome. These necessary changes in the
hormonal state and the shift toward anti-inflammation can, how-
ever, cause a dysregulations in the number and behavior of mast
cells (MCs). MCs have been shown to exhibit beneficial func-
tion in pregnancy by contributing to implantation, placentation
and fetal growth through their release of the glycan-binding pro-
tein galectin-1 and, thus, are critically implied in the fetomaternal
interface (1). In addition, MCs influence pregnancy by modulating
non-immunological responses by contributing to tissue remod-
eling, angiogenesis, and spiral artery modifications (1). In later
pregnancy phases, however, MCs display rather detrimental func-
tions as an excessive release of MC-mediators in parturition are
associated with pre-term delivery. MC activation is modulated
by hormonal endocrine signals that could lead to altered func-
tional behavior of MCs in various innate and adaptive immune
responses (1). In particular, pre-existing MC mediated and asso-
ciated disorders may affect disease progression and the disease
itself may influence pregnancy outcome. Sex hormones are con-
sidered to influence the clinical course and severity of chronic
allergic and inflammatory diseases, including atopic dermatitis
(AD), asthma, and psoriasis (2–5). In fact, estrogen and proges-
terone have been reported to modulate tissue homeostasis and
immunological responses in various conditions.
Here, we review the existent literature on the clinical implica-
tions of MC associated disorders in pregnancy, focusing on directly
MC mediated disease such as urticaria and mastocytosis, but also
summarize the disease impact on pregnancy of common inflam-
matory disorders in which MC have been reported to critically
contribute to the pathogenesis. Hereby, we offer an overview of
how disease-specific modifications in MC function and activation
could determine the fate of pregnancy.
ROLE OF MAST CELLS AND MAST CELL MEDIATORS IN
PREGNANCY
Mast cells reside in the endometrial tissue and uterine MCs exhibit
signs of activation during premenstrual stages (6). MCs gran-
ules consist of a large array of mediators, including histamine,
prostaglandins, leukotrienes, several cytokines, and proteases (7).
The release of MC protease such as tryptase has been reported to
stimulate the production of matrix metalloproteinases (MMPs)
that are involved in the degradation of extracellular matrix com-
ponents. Increase protease expression is detected during menstru-
ation (8). Histamine, which is produced and released by MCs,
has been reported to be involved in blastocyst implantation and
placenta development by contributing to and promoting tro-
phoblast invasion, growth, and the expression of adhesion (9,
10) molecules. During pregnancy, the number of MCs increase
in the myometrium and equal ratio of tryptase and chymase
(MCTC) positive MCs shift toward a tryptase-only (MCT) pheno-
type (11). Here, histamine, prostaglandins and MC proteases have
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been shown to contribute and modulate myometrical contractil-
ity (12, 13). MC proteases may also be involved in post-partum
uterine tissue remodeling (14). Given these facts, it is reasonable
to suggest that MCs influence pregnancy outcome under physio-
logical conditions and even more relevant when their activation
status is modulated by disease. The prevalence of MC mediated
and associated disorders, including allergic and non-allergic dis-
eases, is increasing. Severe allergic reaction, i.e., anaphylaxis during
pregnancy can indeed result in pre-term labor whereas adequate
treatment, including antihistamines and corticosteroids, report-
edly inhibited uterine contractions (15). This evidence points
toward the importance of disease management of MC-related dis-
orders during pregnancy. Although, the use of systemic treatments
should be limited or even generally avoided in pregnancy – espe-
cially in the first trimester, pregnant women require best possible
treatment. But how to provide best possible treatment by calcu-
lated risk profile? The use of second-generation antihistamines
(sgAH) for example is widely used for the treatment of aller-
gic disease. In pregnancy, it is recommended to limit the use of
sgAH to loratadine (16), and possibly desloratadine, because of
best available evidence. Nowadays, several AH are OTC (over-the-
counter) products in many countries and it can be assumed that
these drugs are frequently used by pregnant women – at least
before they knew to be pregnant. However, up-dosing of sgAH as
it is recommended in the management of chronic urticaria must
be carefully suggested in pregnancy since safety studies have not
been performed (17).
URTICARIA IN PREGNANCY
Urticaria is a very common dermatological condition in which
an increased activation of MCs and the subsequent release of
MC-mediators, mainly histamine among others, lead to the devel-
opment of wheal-and-flare responses accompanied by an intense
pruritus on the skin (18). Urticaria is divided into acute (less than
6 weeks) and chronic (more than 6 weeks) forms as well as into
inducible and spontaneous occurring subtypes (17). Urticaria may
develop during pregnancy even though it is not considered as a
specific pregnancy dermatosis. MCs have also been reported to
contribute to the pathogenesis of pregnancy-related dermatoses
associated with pruritus that are restricted to pregnancy, e.g.,
pruritic urticarial papules and plaques of pregnancy (PUPPP).
Urticaria can either develop during pregnancy or the symptoms of
a pre-existing chronic spontaneous urticaria (CSU) may change in
terms of disease activity and severity. Influence of sex hormones
on MC functions and the pathogenesis of CSU have long been
considered (19). CSU is approximately twice more frequent in
women than in men and the disease activity of CSU may be asso-
ciated or triggered by fluctuation of sex hormone levels, including
menstrual cycle, pregnancy, menopause, and hormonal therapies
(19). CSU may worsen with pregnancy in some patients but also
improve in others (20). Hypersensitivity to sex hormones and their
modulating actions on MCs have been implicated in the pathogen-
esis of CSU and altered hormone serum levels have been described
in subgroups of CSU patients (21). Thus, such fluctuations in the
hormonal milieu have been suspected to either improve, main-
tain, or aggravate urticarial lesions during pregnancy (19). PUPPP
and other pregnancy-related dermatoses associated with pruritus
should be considered as differential diagnosis if wheals and itch
newly occur in pregnancy, especially during the third trimester
(22). In addition, special treatment considerations should be
applied to pregnant and lactating women (17, 23).
PRURITIC URTICARIAL PAPULES AND PLAQUES OF
PREGNANCY
Pruritic Urticarial Papules and Plaques of Pregnancy or polymor-
phic eruption of pregnancy (PEP) is the most common pregnancy-
related skin disorder with an incidence of about 1:160–1:200 (24).
This disease appears and exists exclusively in pregnant patients.
Besides the pruritic urticarial papules and plaques,which represent
the key symptoms of PUPPP, more than one-half of the patients
later develop polymorphous features including erythema, vesicles
as well as targetoid and eczematous lesions (25). Characteristically,
the eruptions begin on the abdomen, particularly, within or adja-
cent to striae cutis distensae and occur predominantly in the third
trimester in about 83% of the patients (25–27). It is suggested that
multiple gestations and an excessive maternal weight gain is asso-
ciated with the occurrence of PUPPP (25, 28). The fetal weight
and sex does not seem to be related to the onset of PUPPP (25).
Cortisol serum levels have been found to be significantly reduced
in PUPPP patients whereas estradiol concentrations were compa-
rable with unaffected women (27). It is tempting to speculate that
MCs are involved in the onset of PUPPP although no studies are
existing showing a direct link between MCs and this disease. It is
suggested that the activation of the skin immune system charac-
terized by increased numbers of dentritic cells and activated T cells
in lesional skin contribute to the pathology of PUPPP (29). Skin
infiltrates of macrophages (30) and eosinophils (25, 27) have been
described in affected tissue. Although, a direct implication of MCs
has, as of yet, not been reported in PUPPP there are several lines of
evidence that clearly suggest a role for MCs. First, as in urticaria,
antihistamines are the first line option in the treatment of PUPPP
and are effective in most patients. MCs are considered as the main
source of histamine in the skin (31). Second, even though PUPPP
and urticaria are different diseases there are several similarities in
terms of the clinical symptoms including pruritic erythema and
urticarial lesions. Third, autologous whole blood injections have
been reported as an effective treatment option in PUPPP as it is in
auto-reactive CSU (32, 33). Therefore, even if still speculative it is
not unlikely that the release of MC-mediators critically contribute
to the pathogenesis of PUPPP.
MASTOCYTOSIS AND PREGNANCY
Mastocytosis represents a group of related disorders, each char-
acterized by a pathological accumulation of MCs in one or more
organs ranging from indolent to very rare aggressive forms (34).
Mastocytosis is classified as a rare disease with an estimated preva-
lence of around 1 per 10,000 and dividing cutaneous from sys-
temic forms (35). About 80% of mastocytosis patients carry an
Asp816Val mutation in the catalytic domain of the c-Kit recep-
tor downstream tyrosine kinase in peripheral blood mononuclear
cells (36). This point mutation mediates an increased prolifera-
tive rate of MCs (37). An addition explanation for the increased
numbers of MCs in tissues from mastocytosis patients might be
the enhanced chemotaxis of CD117 positive cells. It is speculated
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that MC progenitor cells bearing the D816V mutation preferen-
tially migrate to SCF produced by stroma cells, endothelial cells,
fibroblasts, and keratinocytes in the skin (38). It could be shown
that MCs present in the lesions express SCF suggesting a potential
autocrine or paracrine growth and differentiation loop for MCs
and lymphoid progenitors (39, 40). Differentiation of the mutant
progenitor cells into mature MCs occurs locally based on the spe-
cific microenvironment. Thus, enhanced MC migration combined
with aberrant proliferation contribute to the extensive MC hyper-
plasia observed in affected tissues (38). Beside the elevated serum
tryptase levels in mastocytosis patients (41), the coexpression of
CD25 antigen in bone marrow MCs turned out as diagnostic
marker in mastocytosis (42, 43). In bone marrow biopsies from
mastocytosis patients, MCs are surrounded by lymphoid aggre-
gates, which consist of a mixture of B and T cells (39, 44). Similar
to MCs, these B and T cells carry the D816V mutation (44).
Between 20% and one third of pregnant women with masto-
cytosis reported a worsening of the diseased-related symptoms
(45, 46). Around 30% experienced a clinical improvement during
the first trimester. In the other half of the affected population,
MC-mediator related symptoms remained unchanged (46). Inter-
estingly, worsening of symptoms was observed during the first
or third trimester (46) when Th1-mediated pro-inflammatory
conditions dominate (47–49). Although, women diagnosed with
mastocytosis are often required to continue the intake of med-
ications including antihistamines during pregnancy the doses are
often decreased because of fetal safety concerns (45). The reduc-
tion in medication as well as an irregular medication intake
could contribute to worsening of mastocytosis symptoms as well.
Undiagnosed and not appropriately treated mastocytosis can be
associated with severe pregnancy complications including fetal
demise (50).
Parturients suffering from mastocytosis that do not undergo
a natural birth represent a particular challenge for anesthesiolo-
gists. During the process of labor, life-threatening complications
may occur, particularly due to the risk of anaphylactoid reactions
triggered by anesthesia. Medications such as glucocorticoids, anti-
histamines, and epinephrine should be available during the critical
phases of labor and the early post-partum period (51).
In general, studies describing the impact of mastocytosis in
pregnancy and vice versa are limited. Thus, one can only speculate
that the unique pregnancy-associated micromilieu composed of
hormones and myriads of mediators contribute to variations in
the disease pattern.
ATOPIC DERMATITIS IN PREGNANCY
Atopic dermatitis is a complex chronic inflammatory condition
in which MCs have been shown to contribute critically to the
pathogenesis and the induction of inflammation and pruritus.
MC number and degranulation is increased in atopic lesions (52).
It is suggested that the invasion and degranulation of MCs within
peripheral nerve bundles may provoke and aggravate itchiness of
AD (53). MC-derived mediators might participate in epidermal
hyperplasia seen in lichenified lesions in AD (54).
Atopic dermatitis is one of the most prevalent dermatoses dur-
ing pregnancy (55, 56) and pregnancy may alter the clinical course
and severity of AD. More than half of pregnant women with
pre-existing AD were reported to experience worsening of their
disease during the second or third trimester (57, 58) when a con-
stant Th2 response is maintained. During pregnancy an immuno-
logic homeostasis tolerating the fetus is of crucial importance.
To prevent fetal rejection, maternal T cell mediated immunity is
modulated. AD is widely accepted as a Th2-dominated disorder.
Therefore, alteration in the Th1/Th2 balance is suggested to pro-
mote AD severity, which is often observed in pregnancy (59). MCs
found in AD lesions are a major source of IL-4 and store higher
amounts of IL-4 compared to MCs in normal skin (60). Exogenous
IL-4 has been shown to be important for the differentiation of T
helper cells into Th2 cells (61). Thus, one can speculate that MCs
participate in the Th1/Th2 switch and therefore disease severity
(Figure 1). Moreover, IL-4 induces the proliferation of fibrob-
lasts (62) and atopic fibroblasts contribute to the pathogenesis of
AD by initiating strong proliferation and differentiation defects in
keratinocytes (63).
Variations in sex hormone concentrations seem to be related
with the severity of AD that is supported by the finding that ca.
one third of women reported a premenstrual deterioration in the
symptoms (57, 58). Sex hormones may also directly influence AD
symptoms by their effects on MCs, mediator release, and IgE pro-
duction (64) (Figure 1). No reported evidence point toward direct
influence of AD on infertility or increased rates of miscarriage,
birth defects, or prematurity (65). However, AD patients that are
more prone to suffer from bacterial or viral super-infection may
be at a higher risk for birth complications including premature
delivery, intrauterine growth restriction, or miscarriage (66). The
application of large doses of triamcinolone acetonide for treat-
ment of AD should be avoided as it was related with intra uterine
growth retardations (67). Therefore, specific considerations about
the treatment strategies in AD during pregnancy will apply to
control the impact of AD progression and complications that may
occur on pregnancy.
ASTHMA AND PREGNANCY
In 2004, the number of people affected by asthma worldwide
was estimated as 300 million with a further increase up to 400
million asthmatics by 2025. The rate of asthma increases as com-
munities adopt western lifestyles and become urbanized (68). It is
assumed that environmental estrogens participate in the develop-
ment of asthma as they induce MC degranulation via the estrogen
receptor-α. These pollutants show estrogen-like activities, tend to
degrade slowly, have a long biological half-life, and bioaccumulate
and bioconcentrate in the food chain (69).
Asthma is characterized by recurrent episodes of airway
obstruction, which reverse either spontaneously or after use
of medication. It is usually associated with bronchial hyper-
responsiveness and evidence of chronic airway inflammation (70).
The earliest text where the term “asthma” was mentioned in a
medical context is in the Corpus Hippocraticum. Several cen-
turies later during the second half of the first century A.D. Are-
taeus the Cappadocian was the first one who dealt with asthma
as an autonomous clinical disease and not as a symptom (71).
One characteristic of asthma is the exaggerated narrowing of the
airways that is caused by contraction and shortening of airway
smooth muscle (ASM) cells. However, the cause of the induced
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FIGURE 1 |The hormonal stimulation of mast cells during
pregnancy might contribute to theTh1/Th2 switch that takes place
in pregnancy. The ever-going increase in estrogen, progesterone, and
cortisol could directly influence the activation status and behavior of
MCs and lead to the release of either pro- or anti-inflammatory
mediators thus contributing to the Th1 or Th2-based micromilieu.
Hence, disorders that are mediated by MCs or in which MCs are
involved may turn into an unfavorable direction. It is however also
possible that the symptoms ameliorate due to the hormone-modulated
behavior of MCs.
displacement behavior of the ASM is still a matter of discussion.
It is proposed that following processes could contribute to the
SMC response: (1) changes in ASM structure and/or behavior; (2)
structural and/or mechanical alterations in the non-contractile
structures of the airway wall, and (3) variations in the relationship
of the airway wall to the surrounding lung parenchyma (72). The
airway remodeling observed during the course of asthma includes
the increase in the smooth muscle cells surrounding the airway
wall, a deposition of extracellular matrix components under the
epithelial basement membrane that causes a thickened appearance,
a breach in the integrity of the airway epithelium and an increase
of mucus-producing goblet cells in the epithelium or submucosal
glands (73).
Various immune cell types including macrophages, eosinophils,
and MCs participate in the process of airway remodeling; accord-
ingly they were found in high numbers in bronchoalveolar lavage
and in bronchial biopsies from asthmatic patients (74). Asthma
is i.a. characterized by an infiltration of MCs in the bronchial
epithelium (75), mucous glands, and smooth muscle (76, 77).
It is hypothesized that the ASM itself induce the migration of
MCs and their progenitors via the release of the chemoattractants
CXCL9, CXCL10, CXCL11, stem cell factor (SCF), and transform-
ing growth factor (TGF)-β (78–80). ASM would also induce MC
proliferation and survival (81). Once resident in the ASM bundle,
MCs adhere to it via cell adhesion molecule 1 (CADM1) (82).
The release of MC-mediators such as histamine, prostaglandin
D2, and leukotriene C4 upon activation induces typical asthmatic
symptoms including bronchoconstriction, mucus secretion, and
mucosal edema (80). It is often assumed that the activation of
MC during asthma is allergen-dependent via the high affinity IgE
receptor FcεRIα. Mucosal MCs present in bronchial tissue from
asthmatic patients exhibit features of chronic activation (83).
About 1% of pregnant women are diagnosed with active asthma
(84). The inflammatory response induced in asthmatic airways
contributes to the pathophysiology of this disease (85). This in
turn could interfere with the necessary variations in the cytokine
milieu mandatory for pregnancy to occur and be maintained. The
first trimester and also the early phases of the second trimester
of pregnancy require a strong inflammatory response in order to
ensure uterine tissue remodeling and clearance of cellular debris
(47–49). During the course of pregnancy, the concentrations of
the steroid hormones estradiol (E2) and progesterone (P4) raise
more than fivefold followed by a further fivefold increase by term
(86). The immunological shift toward Th1 responses at the begin-
ning of pregnancy is mediated by enhancing pro-inflammatory
cytokine production by monocytes and macrophages (87), den-
dritic cells (88) as well as MCs (89) (Figure 1). The ever-going
increase in estrogen, progesterone, and cortisol concentrations at
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midpregnancy supports a shift toward Th2 responses, which are
necessary for maintaining pregnancy (90). As asthma is a classical
Th2-driven disease its course may be negatively influenced by the
establishment of an anti-inflammatory milieu as it is observed in
the second and early third trimester (91). Indeed, during preg-
nancy asthma worsens in 35% of the women with an increase in
asthma symptoms starting at the third trimester (92) when a con-
stant Th2 milieu was established. MCs express the receptors for E2
and P4 (93, 94) and degranulate upon treatment with theses hor-
mones (94). Based on these findings, one might speculate that the
rising levels of estrogens and progesterone during pregnancy stim-
ulate MCs to degranulate (Figure 1) whereby they could negatively
influence the course of asthma. This could be an explanation of
why one third of women present a worsening of asthma symptoms
at midpregnancy (92). However, 28% of the women experienced
an improvement of asthma symptoms and further 33% showed
no changes (92). Women who reported changes in their asthmatic
symptoms during pregnancy reverted post-partum toward their
pre-pregnancy asthma course (92).
An elegant study by Perlow et al. revealed that pregnant women
requiring long term administration of oral steroids are at an
increased risk of pre-term labor and delivery as well as to develop
gestational diabetes (95). Moreover, steroid-dependent (95, 96)
but also non-steroid medicated (95) asthmatic mothers delivered
more often low birth weight neonates with less than 2500 g than
mothers without asthma. Intriguingly, the boost in asthma symp-
toms during pregnancy seems to correlate with the gender of the
fetus. While women who delivered boys reported an improve-
ment in their asthma during their pregnancy, mothers of girls,
however, had increased asthma severity during gestation (97, 98).
Women who were pregnant with a female fetus needed signifi-
cantly more inhaled glucocorticoids in late pregnancy. For this
particular group, it is proposed that an upregulation of inflam-
mation is associated with asthma as gestation progressed (98).
The mechanism behind is not entirely understood. In asthmatic
mothers pregnant with female fetuses, the placental activity of the
enzyme 11-hydroxysteroid dehydrogenase type 2 (11-HSD2) that
metabolizes cortisol to inactive cortisone is reduced (98). This
would increase the intracellular cortisol concentration in relation
to variations in cytokine production in female placentas com-
pared to male placenta explants (99). It was reported that the
inflammatory response of placental trophoblast cells from male
pregnancies after LPS stimulation is boosted probably because of
the enhanced toll-like receptor (TLR)-4 expression in these cells
(100). These fetal gender-specific differences should be taken into
account during pregnancy in asthmatic women.
PSORIASIS AND PREGNANCY
About 25 million people in Europe and North America are
affected by psoriasis that counts to the most prevalent immune-
mediated skin disease in adults (101). Psoriasis is considered to be
a genetically programed, organ-specific (skin, or skin and joints)
inflammatory disease (102) characterized by red, scaly, and raised
plaques (101). Vascular dilation, bridged fenestrations, and gaps
in endothelium, edematous areas in the cytoplasm of endothelio-
cytes, myocytes, and pericytes, basement membrane zone thicken-
ing and cell extravasation are reported as microvascular changes
that occur in psoriatic lesions and represent signs of increased
vascular permeability (103). Compared to asthma, psoriasis is con-
sidered to be a Th1-driven disease characterized by the infiltration
of several T cell subsets, neutrophils, dendritic cells, natural killer
T cells, and MCs (102, 104). All of them contribute to the inflam-
matory microenvironment that is composed of increased levels of
interferon (IFN)-γ, tumor necrosis factor (TNF)-α, IL-2, and IL-
12 (105) as well as IL-23 and IL-17A. MCs have been demonstrated
to be key modulators of T-cell mediated responses and essentially
involved in neutrophil recruitment (106). Recently, the important
role of IL-17 producing Th17 cells in the pathogenesis of pso-
riasis has been reported (107). Neutrophils and MCs are other
significant potential sources of IL-17A in psoriasis (108). In the
superficial dermis of psoriatic skin, MC density is increased (104).
It has been shown that alterations in psoriatic tissue appear to
be initiated by degranulating MCs (109) and MC degranulation
is among the earliest events in relapsing psoriasis lesions (109).
Degranulated MCs have been found in close proximity to blood
vessels in the area of psoriatic lesions (103). One can speculate
that the survival of MCs in the tissue is regulated by their most
important growth factor, the SCF that is intensely expressed in
psoriatic tissue while its receptor KIT is upregulated in the surface
of MCs (110).
Mast cells are typically classified into either MCT that con-
tain only tryptase or MCTC that contain both proteases tryptase
and chymase. Both subtypes in human are suggested to be equiv-
alent to the murine MC phenotypes. While MCT seem to be
related to immunological processes, MCTC appear to be linked
to non-immunological responses including tissue remodeling and
angiogenesis. The tryptase is the quantitatively dominant protease
present in all MC phenotypes (111). In psoriatic skin, tryptase-
positive cells are increased in number (112, 113). However, the
determination of serum tryptase levels is not an appropriate tool
to assess the severity of psoriasis as no correlation could be found
between serum tryptase and psoriasis severity in patients (114).
Tryptase levels in normal subjects are undetectable (<1 ng/ml)
whereas in systemic MC disorders such as mastocytosis and
anaphylaxis elevated tryptase levels can be detected (41).
It was reported that approximately 50% of patients develop pso-
riasis before the age of 25 (115). There are several studies showing
that the natural course of psoriasis in women is modulated by men-
strual cycle, pregnancy, and menopause (5, 115, 116). All of these
events during the reproductive cycle are under hormonal regula-
tion. During pregnancy, more than 50% of the women reported an
improvement of psoriasis at ca. the 30th week of pregnancy (mid-
pregnancy) while more than 20% observed a worsening (116).
At this time point, the shift from Th2 to Th1 immunity occurs
mainly mediated by increased levels of estrogen, progesterone,
and cortisol (90). It is assumed that during pregnancy and when
hormone levels are increased, psoriatic symptoms improve. Dur-
ing puberty, post-partum and menopause when hormone levels
decrease the disease severity seems to peak (117). Several Th1-
characterized diseases including psoriasis (116), multiple sclerosis
(118), and rheumatoid arthritis (119, 120) have been shown to
improve during pregnancy. Psoriatic body surface areas (BSA)
decreased significantly from 10 to 20 weeks’ gestation. Thereby,
increased levels of estrogen relative to progesterone correlate with
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the improvement of psoriasis while progesterone concentrations
alone did not correlate with changes in psoriatic symptoms. Inter-
estingly, post-partum more than 60% of the patients reported
worsening of symptoms while only 8.7% observed an improve-
ment. But the authors found out that the“post-partum flare”was a
return to the patients’ baseline, rather than a real worsening (116).
It was reported that pregnant psoriatic women are at increased
risk to adverse pregnancy outcomes including spontaneous and
recurrent abortion, gestational hypertension, ectopic pregnancy,
and pre-term rupture of membranes (121, 122). In fact, study
results are controversial. Some showed an increased risk of adverse
pregnancy outcomes, others did not. Psoriasis is definitely no con-
traindication for a pregnancy but a well-controlled disease and the
monitoring of comorbidities, such metabolic syndrome, during
pregnancy is of advantage. In contrast, generalized pustular psori-
asis of pregnancy (GPPP), a special subtype of psoriasis occurring
during pregnancy might be harmful for mother and child (123).
In such cases, women should be kept on medical care by der-
matologists. Several medications are available whose suitability
and unsuitability for the treatment of psoriasis during pregnancy
are reviewed by Lam et al. (124). However, safety data are lim-
ited because most of the data are based on case reports, which
lack the comparison group of untreated patients (124). Women
who need a disease-specific treatment should keep in mind that
leaving a disease untreated during pregnancy may carry a greater
risk to both the mother and fetus than any teratogenic risk of
the drug to the fetus (124). Systemic treatment should be avoided
when possible, but if necessary the best treatment option should
be chosen on a case to case basis for optimized treatment during
pregnancy.
RESUME
In general, there is no contraindication to pregnancy when MC-
related pathologies are under appropriate medical control. Women
who were diagnosed with MC mediated or associated disorders
and especially those whose disease is active, should be carefully
advised by medical specialists to avoid severe pregnancy compli-
cations and to monitor disease progression. The unique modifica-
tions of the maternal endocrine and immune system can influence
the number and behavior of MCs. Further studies addressing the
molecular mechanisms behind the impact of pregnancy on MC
mediated and associated disorders are needed in order to optimize
pregnancy course and outcome.
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